Gyre Therapeutics
GYRE
65 hedge funds and large institutions have $75.5M invested in Gyre Therapeutics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 31 reducing their positions, and 16 closing their positions.
5,982% more call options, than puts
Call options by funds: $5.11M | Put options by funds: $84K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.79% less ownership
Funds ownership: 8.61% → 7.81% (-0.79%)
6% less funds holding
Funds holding: 69 → 65 (-4)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
14% less capital invested
Capital invested by funds: $87.7M → $75.5M (-$12.2M)
71% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 31
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$2.6M |
| 2 |
PVI
Pura Vida Investments
New York
|
+$1.63M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$464K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$287K |
| 5 |
JGC
J. Goldman & Co
New York
|
+$267K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Group One Trading
Chicago,
Illinois
| – | -$28.6K | -868 | Closed |
|
77
UBS Group
Zurich,
Switzerland
| – | -$11K | -348 | Closed |
|
78
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$9K | -290 | Closed |
|
|
FDCDDQ
79
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$4.87K | -150 | Closed |
|
|
QCG
80
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$1K | -45 | Closed |
|
81
New York State Common Retirement Fund
Albany,
New York
| – | -$1K | -34 | Closed |
|
GYRE Hedge Fund Activity: Q3 2021 in Review
65 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2021, worth a combined $75.5M — down 14% from $87.7M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of GYRE and 14 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 9 added.
The largest buyer was OrbiMed, adding an estimated $2.6M. The largest seller was Stonepine Capital Management, cutting an estimated $1.94M.
- 65 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2021, down from 69 in Q2 2021.
- Funds reported $75.5M of Gyre Therapeutics stock for Q3 2021, down 14% quarter-over-quarter.
- 14 funds opened new Gyre Therapeutics positions in Q3 2021 and 16 closed out, a net change of -2 holders.
- The largest Gyre Therapeutics buyer in Q3 2021 was OrbiMed, an estimated $2.6M added.
- The largest Gyre Therapeutics seller in Q3 2021 was Stonepine Capital Management, an estimated $1.94M sold.
Based on aggregated 13F filings for Q3 2021.